Nothing Special   »   [go: up one dir, main page]

CO5550439A2 - Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen - Google Patents

Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen

Info

Publication number
CO5550439A2
CO5550439A2 CO04009120A CO04009120A CO5550439A2 CO 5550439 A2 CO5550439 A2 CO 5550439A2 CO 04009120 A CO04009120 A CO 04009120A CO 04009120 A CO04009120 A CO 04009120A CO 5550439 A2 CO5550439 A2 CO 5550439A2
Authority
CO
Colombia
Prior art keywords
arilsulfonil
piperazina
affinity
receptor
pharmaceutical compositions
Prior art date
Application number
CO04009120A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5550439A2 publication Critical patent/CO5550439A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

1.- Un compuesto de fórmula en dondeAr es naftilo o fenilo, opcionalmente sustituido por halógeno o (C1-C6)-alcoxilo;R1 es (C1-C6) -alquilo;R2 es hidrógeno o (C1-C6)-alquilo;o sus sales o solvatos farmacéuticamente aceptables.
CO04009120A 2001-08-10 2004-02-05 Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen CO5550439A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31150401P 2001-08-10 2001-08-10
US38471102P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
CO5550439A2 true CO5550439A2 (es) 2005-08-31

Family

ID=26977917

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04009120A CO5550439A2 (es) 2001-08-10 2004-02-05 Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen

Country Status (20)

Country Link
US (1) US6825202B2 (es)
EP (1) EP1423106B1 (es)
JP (1) JP4187650B2 (es)
KR (1) KR100608417B1 (es)
CN (1) CN1254469C (es)
AT (1) ATE417838T1 (es)
AU (1) AU2002340804B2 (es)
CA (1) CA2456250A1 (es)
CO (1) CO5550439A2 (es)
DE (1) DE60230424D1 (es)
ES (1) ES2316619T3 (es)
HR (1) HRP20040090A2 (es)
HU (1) HUP0401235A2 (es)
IL (1) IL159880A0 (es)
MX (1) MXPA04001250A (es)
NO (1) NO326497B1 (es)
NZ (1) NZ530742A (es)
PL (1) PL373397A1 (es)
RU (1) RU2268884C2 (es)
WO (1) WO2003014097A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
WO2004041792A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
PT1831159E (pt) * 2004-12-21 2010-03-03 Hoffmann La Roche Derivados de tetralina e de indano e as suas utilizações
EP1695971A1 (en) * 2004-12-30 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Substituted phenyl-piperazine compounds, their preparation and use in medicaments
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CA2759491A1 (en) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
ES2536779T3 (es) * 2009-04-30 2015-05-28 Abbvie Deutschland Gmbh & Co Kg Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3134392B1 (en) 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU551871A1 (ru) * 1974-03-26 1981-09-07 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латсср 2-Арилпиперазино-2-фенилинданоны,обладающие психотропными свойствами
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) * 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
PE20020063A1 (es) * 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht

Also Published As

Publication number Publication date
HK1070054A1 (en) 2005-06-10
NO326497B1 (no) 2008-12-15
IL159880A0 (en) 2004-06-20
US6825202B2 (en) 2004-11-30
KR20040023738A (ko) 2004-03-18
JP2005502649A (ja) 2005-01-27
AU2002340804B2 (en) 2008-04-03
EP1423106B1 (en) 2008-12-17
CN1254469C (zh) 2006-05-03
US20030069254A1 (en) 2003-04-10
CA2456250A1 (en) 2003-02-20
NO20040589L (no) 2004-03-19
ATE417838T1 (de) 2009-01-15
PL373397A1 (en) 2005-08-22
DE60230424D1 (en) 2009-01-29
HUP0401235A2 (hu) 2004-10-28
NZ530742A (en) 2007-07-27
ES2316619T3 (es) 2009-04-16
KR100608417B1 (ko) 2006-08-02
CN1541210A (zh) 2004-10-27
RU2268884C2 (ru) 2006-01-27
HRP20040090A2 (en) 2004-12-31
MXPA04001250A (es) 2004-05-27
RU2004107261A (ru) 2005-09-10
WO2003014097A1 (en) 2003-02-20
JP4187650B2 (ja) 2008-11-26
EP1423106A1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
CO5550439A2 (es) Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
ATE297910T1 (de) Retinoid x rezeptormodulatoren
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
HUP0400467A2 (hu) 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CR10145A (es) Derivados de tropano útiles en terapia (divisional exp. 6800)
AR034792A1 (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20026094L (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
AU3415599A (en) Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
EE04814B1 (et) Tetrahüdropüridiinid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
MX9600816A (es) Nuevos derivados triciclicos, su preparacion, su aplicacion a la preparacion de la colquicina y de la tiocolquicina, opticamente activas o racemicas, y de compuestos analogos o derivados e intermedios.

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed